Helix BioPharma Corp. has completed an agreement with ProMab Biotechnologies, Inc. to develop a cell-based therapy to prevent and treat solid tumors.
The Richmond, Ontario-based company will collaborate with ProMab to develop chimeric antigen receptor T cell, or CAR-T, technologies for certain hematological malignancies.
The identified treatment will be developed for multiple myeloma, a type of blood cancer. Helix retains the commercial rights to the CAR-T cell therapy in Canada and Europe.
The program intends to start human trials by early 2019.
Helix said it continues to prioritize its DOS47 drug development, particularly its clinical L-DOS47 and V-DOS47 preclinical programs, both for treating cancers.